During pregnancy, immunological tolerance towards the semi-allogeneic fetus needs to be 58 established whilst at the same time an effective immune defense must be maintained 1 . The 59 pregnancy-associated thymic involution reported in rodents 2 has been suggested to support 60 maternal immune regulation by reducing the output of potentially harmful T helper (Th) cells. 61
However, the functional importance of this thymic involution remains unclear and it is not known if it 62 even occurs in humans 3 . In fact, the role of thymus during human pregnancy and in pregnancy-63 associated tolerance remains largely unknown 4 , albeit a role for thymic-derived T regulatory (Treg) 64 cells in pregnancy complications has been suggested 4 , supporting a role for thymus in immune 65 regulation during human pregnancy. The aim of this study was to assess the role of thymus in Th-cell 66 regulation during human pregnancy by analyzing the output of different Th-cell populations. 67
68
To determine if pregnancy influences thymic function we used RT-PCR to analyze T cell receptor 69 excision circle (TREC) content in flow cytometry sorted Th-cell subpopulations (Fig 1, A-B ) in 2 nd 70 trimester pregnant and non-pregnant women (see detailed methods and Table E1 in this article's 71
Online Repository at www.jacionline.org). TREC content is a well-established measure of cells with 72 recent thymic origin 5 , based on the presence of episomal DNA fragments, generated during the T cell 73 receptor rearrangement in the thymus, and since TRECs are not duplicated during mitosis they are 74 diluted with each cell division. Consequently, cells with a more recent thymic origin will have a higher 75 TREC content compared with Th-cells that have undergone peripheral post-thymic proliferation 5 . As 76 expected, TREC content was significantly higher in cells with a naive (CD45RA + ) phenotype, 77 compared with memory (CD45RA -) cells (p=<0.0001; Fig 1, C) , hence validating our PCR assay to 78 measure TREC. We found that 2 nd trimester pregnant, compared with non-pregnant, women had 79 significantly higher TREC levels (p=0.043: Fig 1, D) in the naive Treg population (defined as 80 CD25 ++ CD45RA + Foxp3 + ), indicating an increased thymic output of Treg cells in pregnancy. The TREC 81 content did not differ in the naive T conventional (Tconv; CD25 -CD45RA + ) cells (Fig 1, E) , in line with a 82 maintained output of conventional Th-cells in pregnancy. 83
84
To corroborate and extend the finding of maintained or increased thymic output during pregnancy, 85 we used CD31 expression, assessed by flow cytometry, as an additional marker of recent thymic 86 emigrants (RTEs) 6 . Here, we investigated thymic output in both the 2 nd and 3 rd trimesters of 87 pregnancy, i.e. the period when pregnancy-induced immune modulation is most pronounced (Fig 2,  88 A and see Table E1 and Fig E1 in are known to correlate, although with a slight difference in dynamics 8 . Overall, we found that 93 pregnant and non-pregnant women had similar proportions and absolute numbers of RTE Tconv 94 (CD31 + Foxp3 -CD45RA + ) cells (Fig 2, B-C) , supporting a maintained output of the majority of T cells 95 during pregnancy. The significantly higher RTE Tconv cell count that was noted in 3 rd trimester 96 compared to 2 nd trimester pregnant women (p=0.0036, Fig 2, C) most likely reflects the 97 corresponding increase noted in total CD4+ T cell counts in the 3 rd trimester (compared to the 2 nd 98 trimester, p=0.0067; data not shown). In contrast to the TREC-based difference in Treg cells, we 99 found no differences between non-pregnant and pregnant women, neither in the 2 nd nor in the 3 rd 100 trimester, concerning the proportion and absolute numbers of RTE Treg cells (CD31 + 101 Foxp low CD45RA + ) (Fig 2, D-E ). This was also true for the cellular level of expression of CD31 (median 102 fluorescent intensity; data not shown). The reason why CD31 findings did not corroborate the TREC-103 based increase in the Treg population might be the difference in dynamics of these markers. Indeed, 104 CD31 expression is maintained on naive T cells for several rounds of homeostatic proliferation whilst 105 TREC levels decrease 8 , supporting the notion that differences in kinetics may well explain the 106 difference in our findings regarding Treg cells when based on CD31 (maintained output) or TREC 107 (increased output). 108
109
Proliferation of T cells influences TREC levels, although proliferation in naive T cells is assumed to be 110 too low to significantly affect TREC levels. However, indications of a more activated maternal 111 immune system during pregnancy 9 prompted us to make a more detailed analysis of the dynamics of 112 the T cell pool (for gating strategies see Fig www.jacionline.org). Another factor that potentially could affect measured RTE frequencies, and 120 hence also TREC content, is peripheral consumption, leading to a different distribution of 121 subpopulations. However, we found no major shifts in the T cell distributions as pregnant and non-122 pregnant women had similar proportions of mature naive (CD31 -CD45RA + ) and memory Tconv and 123
Treg cells, as well as of non-suppressive Foxp3 + Th cells (see Fig E4 in this article's Online Repository 124
at www.jacionline.org). Taken together, it is unlikely that peripheral events such as proliferation and 125 consumption of cells have had a large impact on our results. 126
127
In conclusion, we found that thymic output of both Tconv and Treg cells is maintained during 128 2 nd and 3 rd trimester human pregnancy. The output of Treg cells may even be increased, which would 129 fit with the demand for fetal tolerance during pregnancy and could also contribute to the pregnancy-130 associated improvement of autoimmune diseases, like multiple sclerosis, that are associated with 131 defects in thymic function. Our findings challenge the general conception, based on studies in 132 rodents, of an inactive thymus during pregnancy, but rather support a maintained and important 133 function of thymus in human pregnancy. Norrköping, Sweden, were included in the study. A review of medical records following delivery, 14 showed that two pregnant women (recruited in the 2 nd trimester) had delivered preterm (before 15 gestational week 37) and were therefore not considered as normal pregnancies and were excluded. 16
In addition, one woman (2 nd trimester) who received Tinzaparin (Innohep) three days prior to blood 17 sampling was also excluded due to the potential immunological effects of low-molecular weight 18 heparin E1 . Of the remaining 27 2 nd trimester pregnant women (see Table E1 in this article's Online 19
Repository at www.jacionline.org), it was decided that the following three women should remain 20 included: one woman who subsequently developed intra-hepatic cholestasis but delivered at term 21 (gestational week 42), hence considered healthy at the time of blood sampling; one woman on anti-22 histamine (Cetirizine) treatment; one woman on selective serotonin reuptake inhibitor (SSRI) and 23 inhalation budesonide (Pulmicort) treatment. Of the 26 included 3 rd trimester pregnant women (see 24 table E1 in this article's Online Repository at www.jacionline.org), it was decided that the following 25 women should remain included: two women on SSRI; two women on Trombyl and three women who 26 used of pain medication (Citodon). Thirty non-pregnant women were recruited amongst students 27 and personnel at Linköping University and Linköping University Hospital (see Table E1 in this article's 28 Online Repository at www.jacionline.org). All non-pregnant women were healthy and had normal 29 blood cell counts. One non-pregnant control reported use of inhalation budesonide (Pulmicort) and 30 terbutaline sulfate (Bricanyl Turboinhaler) treatment and two controls used SSRIs. There were no 31 significant differences between the groups in terms of age, smoking or parity. The pregnant women 32 had been pregnant significantly more times compared to the non-pregnant controls (p=0.012 for 2 nd 33 trimester vs. HC and p=0.004 for 3 rd trimester vs HC). Due to limitations in cell numbers available 34 from each woman, different numbers of subjects are included in the different analysis. All women 35 gave written informed consent prior to inclusion and blood sampling. The study was approved by the 36 regional ethical review board in Linköping (M39-08). The CD4 + T cells were labelled with mouse anti-human CD4-PeCy7 (clone SK3), CD45RA-V450 52 (clone HI100) and CD25-APC (clone M-A251; all from BD Biosciences) for 30 minutes (min) at 4°C in 53 the dark and washed in phosphate buffered saline (PBS, pH 7.4; Medicago, Uppsala, Sweden) 54 supplemented with 0.1% heat-inactivated fetal bovine serum (FBS; HyClone, GE Healthcare, Little 55 Chalfont, UK) by centrifugation at 500xg, 4°C for 5 min. CD4 + T cells were sorted into different T cell 56 subpopulations based on their expression of CD25 and CD45RA (Fig 1, A) . Naive (CD4 + CD25 -CD45RA + ) 57 and memory (CD4 + CD25 -CD45RA -) T conv cells, naive (CD4 + CD25 ++ CD45RA + ) and memory 58 (CD4 + CD25 +++ CD45RA -) Treg cells were gated using a similar gating strategy as described by Miyara et 59 al. E2 . The CD25 +++ gate for memory Treg cells was based on the lowered expression of CD25 on naive 60
Treg cells (CD25 ++ ) which in turn was set to include cells with a lower CD25 expression whilst still 61 being positive. The CD25gate for the Tconv cells was set to include a major proportion of the CD25 -62 cells while avoiding potential contamination of CD25 dim -expressing cells. Naive (CD45RA + ) and 63 memory cells (CD45RA -) were set based on the contour of the positive and negative populations. We 64 set stricter gates for both CD25 and CD45RA to ensure high purity of the sorted populations (Fig 1,  65   A) . 66
The cells were sorted using the FACSAria III Cell sorter (BD Biosciences) with a 70 µM nozzle 67 and collected in PBS with 0.5% FBS. After sorting, the cells were centrifuged and lysed in Buffer RLT 68 Plus (Qiagen, Hilden, Germany) and stored at -70°C until RNA and DNA extraction. The mRNA expression of Foxp3, the lineage-specific transcription factor for Treg cells, was also 90 analyzed in a portion of the sorted T cell populations (Fig 1, B) . RNA was converted to cDNA using the 91 high-capacity cDNA reverse transcription kit (Applied Biosystems) according to the instructions 92 provided by the manufacturer. Thermal cycling was carried out using the Arktik ™ Thermal Cycler 93 (Thermo Scientific, Waltham, MA, USA). The reaction was carried out by mixing 4 µl (Foxp3) 
